Ranitidine Tablets recalled over manufacturing violations
- Recall date
- December 20, 2019
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Official notice title
- Denton Pharma, Inc. recalls Ranitidine Tablets, USP 150 mg , a). 4 count bottle (NDC 70934-017-04), b). 20-count bottle (NDC 70934-017-20), c). 24-…
- Recall number
- D-0794-2020
- FDA classification
- Class II
- Brand / firm
- Denton Pharma, Inc.
- Sold / distributed
- Nationwide
Why it was recalled
CGMP Deviations: Presence of NDMA impurity detected in product.
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
Ranitidine Tablets, USP 150 mg , a). 4 count bottle (NDC 70934-017-04), b). 20-count bottle (NDC 70934-017-20), c). 24-count bottle (NDC 70934-017-24) d). 30-count bottle (NDC 70934-017-30) e). 90-count bottle (NDC 70934-017-90), Rx Only, Repackaged by: Northwind Pharmaceuticals North Brenheim, NY 12131.
Get recall alerts
Free email alert whenever Denton Pharma, Inc. has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Denton Pharma, Inc.